[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-tumor":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,99,122,149,178,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100624030","phase-1-5-azacitidine-plus-pd-1pd-l1-inhibitor-with-pd-1pd-l1-refractory-tumors-100624030",false,"NCT07404332","5-Azacitidine Plus PD-1\u002FPD-L1 Inhibitor With PD-1\u002FPD-L1 Refractory Tumors","Phase I Study of 5-Azacitidine Plus PD-1\u002FPD-L1 Inhibitor in Patients With PD-1\u002FPD-L1 Refractory Tumors","Inclusion Criteria:\n\n* Written and voluntary informed consent.\n* At least 18 years of age or older.\n* Histologically and radiologically confirmed locally advanced or metastatic unresectable solid tumor malignancy for which PD-1 or PD-L1 therapy is already approved by the FDA. Locally advanced is defined as unresectable in the opinion of the treating physician. A repeat biopsy is required if previous biopsy tissue is unavailable.\n* At least one Response Evaluation Criteria in Solid Tumors (RECIST 1.1) - defined target lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 (fully active, able to carry on all pre-disease performance without restriction), 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work), or 2 (ambulatory and capable of self-care but unable to carry out any work activities, spending more than 50% of waking hours up and about).\n* Documented progression on PD1 or PD-L1 inhibitors.\n* Recovery from any acute toxicity associated with prior therapy to grade 1.\n* Renal function (creatinine level within normal institutional limit, or creatinine clearance \\>15 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal, calculated using the Cockcroft-Gault formula).\n* Liver function (AST\u002FALT \\\u003C3.0 X institutional upper limit of normal OR \\\u003C5 X institutional upper limit of normal in cases of liver metastasis; total bilirubin ≤ 1.5 times upper limit of normal).\n* Adequate hematological lab values including:\n\n  * Absolute Neutrophil Count (ANC) ≥ 1.0 X 109\u002FL\n  * Platelets ≥ 100X109\u002FL\n  * Hemoglobin ≥ 7.0 g\u002FdL\n* Female subjects of childbearing potential and non-sterilized male subjects who intend to be sexually active during the study must agree to use a highly effective method of contraception from time of screening, throughout the whole duration of the drug treatment, and during the 6-month post-treatment washout period.\n* Patients may have previously received a hypomethylating agent, as long as it was not given in combination with ipilimumab.\n* Patients may have previously received ipilimumab but must have relapsed or progressed while on therapy.\n* Patients must have adequate archival tissue available for the purpose of downstream methylation status assessment, immunohistochemistry, RNA expression (10 slides at 5µM). If archival tissue is not available, a repeat biopsy is required.\n\nExclusion Criteria:\n\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with active, untreated metastases in the central nervous system.\n* Patients who are pregnant or breastfeeding.\n* Patients who have an active infection.\n* Patients with significant hematologic, hepatic, and renal function impairment.\n* Patients who are being treated for any concurrent medical condition requiring the use of systemic steroids or history of long-term use of systemic steroids.\n* Patients who have a history of inflammatory bowel disease or a history of symptomatic autoimmune disease.\n* Patients who have had any major surgical procedure or significant traumatic injury within 28 days prior to study enrollment.\n* Patients who have received chemotherapy, immunosuppressive agents or any investigational drug within 28 days prior to starting the study drugs.\n* Patients who have any underlying medical condition which, in the treating physician's opinion, will make the administration of study drugs hazardous or obscure the interpretation of adverse events.","ALL","18 Years","99 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1\u002FPD-L1 inhibitors in patients with tumors refractory to PD-1\u002FPD-L1 inhibitors, for which such treatments have been approved.",[27,28,29],"Solid Tumor","Locally Advanced Solid Tumor","Metastatic Tumor","RECRUITING","2026-05-22",{"date":33,"type":34},"2026-05-28","ACTUAL",{"date":36,"type":34},"2026-02-11",{"date":38,"type":21},"2031-02-28",{"name":40,"class":41},"Mohammed Milhem","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":81,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100561192","phase-1-a-study-with-nkt3964-for-adults-with-advancedmetastatic-solid-tumors-100561192","NCT06586957","A Study With NKT3964 for Adults With Advanced\u002FMetastatic Solid Tumors","A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n\\- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only: subjects must be refractory to, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.\n\nDose Escalation:\n\n1. Ovarian cancer\n2. Endometrial cancer (only endometrioid subtype will require CCNE1 amplification)\n3. Gastric, gastroesophageal junction (GEJ) or esophageal adenocarcinoma with CCNE1 amplification\n4. Small cell lung cancer (SCLC)\n5. Triple-negative breast cancer (TNBC; HER2, estrogen receptor and progesterone receptor negative)\n6. HR+ (includes estrogen-receptor or progesterone-receptor) and HER2- breast cancer (must have progressed following treatment with a CDK4\u002F6 inhibitor, and is not suitable for endocrine therapy \\[ET\\])\n7. Other solid tumors with CCNE1 amplification\n\nDose Expansion:\n\nPart 2A: HR+ and HER2- breast cancer that is locally advanced and unresectable (Stage III) or metastatic (Stage IV); previously treated with ≥1 line of standard of care (SOC) including CDK4\u002F6 inhibitor plus ET and not suitable for further ET. Subjects must have progressed after receiving therapy for ≥3 months in the metastatic setting or for ≥6 months in the adjuvant setting. Subjects must have received ≤2 lines of systemic cytotoxic therapy (chemotherapy or cytotoxic antibody drug conjugate \\[ADC\\]) in the metastatic setting..\n\nPart 2B: Advanced platinum-based-chemotherapy resistant or refractory epithelial ovarian\u002Ffallopian\u002Fprimary peritoneal carcinoma or clear cell ovarian cancer (defined as recurrence ≤6 months after completing platinum-based regimen) with progression on at least one platinum containing therapy and previously treated with ≤4 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease and with CCNE1 amplification.\n\nPart 2C: Advanced unresectable or metastatic gastric, GEJ or esophageal adenocarcinoma with progression on at least one systemic therapy and previously treated with ≤3 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease, with CCNE1 amplification as determined by NGS by local liquid or tissue test.\n\nPart 2D: Advanced endometrial adenocarcinoma or uterine papillary serous carcinoma previously treated with ≤4 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease with CCNE1 amplification.\n\nPart 2E: Advanced\u002Frecurrent uterine carcinosarcoma previously treated with 1 prior platinum-based chemotherapy regimen and ≤3 prior lines of systemic therapy. Prior bevacizumab or PARP inhibitors are allowed and must be at least 3 weeks prior to the start of study drug.\n\n* Have adequate organ function\n* Subjects with female reproductive organs must be surgically sterile, post-menopausal, or must be willing to use highly effective method(s) of contraception\n* Ability to swallow oral medications.\n* Consent to provide archived tumor tissues and paired tumor biopsy at pretreatment\n\nExclusion Criteria:\n\n* Locally advanced solid tumor that is a candidate for curative treatment through radical surgery and\u002For radiotherapy, or chemotherapy.\n* History of another malignancy with exceptions\n* History of lymphohistiocytic or lymphoid hyperplasia; hemophagocytic lymphohistiocytosis.\n* Failed to recover from effects of prior anticancer treatment therapy to baseline or Grade ≤ 1 severity (per CTCAE)\n* Clinically significant cardiovascular event within 6 months prior to start of NKT3964 treatment\n* Known active CNS metastases and\u002For carcinomatous meningitis\n* Active interstitial lung disease currently requiring treatment\n* History of uveitis, retinopathy or other clinically significant retinal disease\n* Active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease\n* Active wound healing from major surgery within 1 month or minor surgery within 10 days before the first dose of NKT3964.\n* Known human immunodeficiency virus (HIV), active hepatitis B or C infection\n* Prior investigative treatment with a selective or nonselective CDK2 inhibitor or degrader\n* Childs-Pugh class B or C cirrhosis or any other clinically significant liver disorder\n* Palliative radiation therapy within 14 days or other radiation therapy within 4 weeks prior to C1D1",{"count":51,"type":21},150,[24],"The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).",[27,55,56,29,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80],"Advanced Solid Tumor","Solid Tumor, Adult","Ovarian Cancer","Ovarian Neoplasms","Ovarian Carcinoma","Metastatic Ovarian Carcinoma","Endometrial Neoplasms","Endometrial Diseases","Metastatic Endometrial Cancer","Triple Negative Breast Cancer","Metastatic Endometrial Carcinoma","Advanced Endometrial Carcinoma","Advanced Ovarian Carcinoma","Gastric Cancer","Advanced Gastric Carcinoma","Metastatic Gastric Cancer","Metastatic Gastric Carcinoma","Small Cell Lung Cancer","Small Cell Lung Carcinoma","Triple Negative Breast Neoplasms","Platinum-resistant Ovarian Cancer","Platinum-refractory Ovarian Carcinoma","CCNE1 Amplification","Hormone Receptor Negative Breast Carcinoma","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Progesterone-receptor-positive Breast Cancer",[82,83,84,85,86,87],"CDK 2 Inhibitor","CDK 4 Inhibitor","CDK 6 Inhibitor","CDK2 Degrader","Protein Degrader","PROTAC","2026-04-16",{"date":90,"type":34},"2026-04-21",{"date":92,"type":34},"2024-09-19",{"date":94,"type":21},"2029-05",{"name":96,"class":97},"NiKang Therapeutics, Inc.","INDUSTRY",19,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100494360","phase-3-a-randomized-phase-iii-trial-of-stereotactic-ablative-radiotherapy-for-patients-with-up-to-10-oligometastases-and-a-synchronous-primary-tumor-100494360","NCT05717166","A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.","SABR-SYNC","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing to provide informed consent\n* Karnofsky performance status \\> 60\n* Life expectancy \\> 6 months\n* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n* Total number of metastases 1-10 at the time of enrollment, with a primary tumor also present\n* Restaging completed within 12 weeks prior to randomization (see section 5.1)\n* For patients receiving thoracic radiotherapy, the enrolling physician must confirm there are no computed tomography (CT) changes suggestive of fibrotic interstitial lung disease (ILD) (i.e. reticular changes, traction bronchiectasis, or honeycombing) reported on any prior CT scans. If any are present, the patient must be assessed by a respirologist to rule out ILD prior to enrollment.\n* 10 or fewer lifetime metastases from the cancer for which participants are being enrolled\n\nExclusion Criteria:\n\n* Serious medical comorbidities precluding radiotherapy. These include ILD in patients requiring thoracic radiation, Crohn's disease in patients where the gastrointestinal (GI) tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.\n* For patients with liver metastases, moderate\u002Fsevere liver dysfunction (Child Pugh B or C); please see the Child-Pugh score calculator.\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix 1. All such cases must be discussed with a member of the study steering committee.\n* Malignant pleural effusion\n* Inability to treat all sites of disease\n* Brain metastasis \\> 3 cm in size or a total volume of brain metastases greater than 30 cc.\n* Metastasis in the brainstem\n* Clinical or radiologic evidence of spinal cord compression\n* Metastatic disease that invades any of the following: GI tract (including esophagus, stomach, small or large bowel), or skin\n* Pregnant or lactating women",{"count":107,"type":21},180,[109],"PHASE3","This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease.\n\nPatients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10).",[29],"2025-12-24",{"date":114,"type":34},"2025-12-31",{"date":116,"type":34},"2023-10-06",{"date":118,"type":21},"2029-04",{"name":120,"class":41},"David Palma",5,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":42},"100479074","phase-1-a-clinical-study-of-cd70-targeted-car-t-in-the-treatment-of-cd70-positive-advancedmetastatic-solid-tumors-100479074","NCT05518253","A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced\u002FMetastatic Solid Tumors","A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n1. Age ≥18 years old, male or female;\n2. Histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) diagnosed as advanced\u002Fmetastatic solid tumor (positive tumor CD70 expression (tumor CD70 positive (IHC 3+) confirmed by histology or pathology));\n3. Failure or intolerance after standard treatment (disease progression or intolerance such as surgery, chemotherapy, radiotherapy, targeted therapy, etc.), and there is currently no effective treatment;\n4. According to the RECIST version 1.1 standard, at least one target lesion with measurable diameter and evaluable, measurable lesions are defined as: extranodal CT scan long diameter ≥ 10mm, lymph node lesions CT scan short diameter ≥ 15mm, scan slice thickness Not larger than 5mm, and has not received local treatment;\n5. ECOG 0-2 points;\n6. The expected survival time is more than 12 weeks;\n7. No serious mental disorder;\n8. The function of important organs is basically normal:\n\n   1. Hematopoietic function: neutrophils\\>1.0×109\u002FL, platelets\\>75×109\u002FL, hemoglobin\\>80g\u002FL;\n   2. Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram;\n   3. Renal function: serum creatinine≤2.0×ULN;\n   4. Liver function: ALT and AST ≤2.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤3.0×ULN);\n   5. Total bilirubin ≤2.0×ULN (Gilbert syndrome or combined liver tumor infiltration can be relaxed to ≤3.0×ULN);\n   6. Oxygen saturation \\> 92% in non-oxygen state.\n9. Have apheresis or venous blood collection standards, and have no other contraindications for cell collection;\n10. Subjects agree to use reliable and effective contraceptive methods for contraception (excluding safe period contraception) within 1 year after signing the informed consent form to receiving CAR-T cell infusion;\n11. Subjects or their guardians agree to participate in this clinical trial and sign the ICF, indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the research.\n\nExclusion Criteria:\n\n1. Received anti-CD70 drug treatment before screening;\n2. Active\u002Fsymptomatic central nervous system metastases or meningeal metastases at the time of screening; subjects with brain metastases who have been treated must be confirmed to have no imaging-proven progression ≥4 weeks after the end of treatment before they can be enrolled;\n3. Received any of the following treatments prior to screening:\n\n   1. Participated in other interventional clinical studies before screening, including: the last use of unmarketed new drugs is less than 3 months before cell reinfusion, or the last use of marketed drugs is less than 5 half-lives from cell reinfusion;\n   2. Received anti-tumor therapy such as chemotherapy and targeted therapy within 2 weeks or at least 5 half-lives (whichever is shorter) before apheresis;\n   3. Received systemic corticosteroid therapy at doses greater than 10 mg\u002Fday prednisone (or equivalent doses of other corticosteroids) within 2 weeks prior to apheresis (inhalation or topical is allowed in the absence of active autoimmune disease Use steroids and adrenal corticosteroid replacement at doses greater than 10 mg\u002Fday of prednisone);\n   4. Received live attenuated vaccine within 4 weeks before screening;\n4. Active infection or uncontrollable infection requiring systemic treatment within 1 week before screening;\n5. Malignant tumors other than the target tumor within 3 years prior to screening, except for the following: malignant tumors that have received radical treatment and no known active disease within ≥ 3 years prior to enrollment; or adequately treated of non-melanoma skin cancers with no evidence of disease;\n6. Have any of the following heart conditions:\n\n   1. New York Heart Association (NYHA) stage III or IV congestive heart failure;\n   2. Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment;\n   3. Clinically significant ventricular arrhythmia, or a history of unexplained syncope (except those caused by vasovagal or dehydration);\n   4. History of severe nonischemic cardiomyopathy.\n7. Known to have active or uncontrolled autoimmune diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, etc.;\n8. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA titer test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive; cytomegalovirus (CMV) DNA test positive;\n9. The subject has experienced venous thromboembolic events (eg: pulmonary embolism) and still needs anticoagulation therapy, or meets the following conditions: a. Bleeding with grades 3 to 4 for more than 30 days; b. venous thrombosis Sequelae (such as persistent dyspnea and hypoxia); (Note: although subjects with venous thrombosis but not meeting the above conditions can participate in the trial);\n10. Poorly controlled hypertension, defined as systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg (blood pressure values measured based on the average of 3 readings at least 2 minutes apart, blood pressure ≥ 150\u002F90 mmHg at initial screening is acceptable Antihypertensive treatment, screening can be performed if the blood pressure is less than 150\u002F90mmHg and well controlled after treatment);\n11. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving CAR-T cell reinfusion;\n12. Other investigators deem it inappropriate to participate in the study.",{"count":130,"type":21},30,[24],"This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced\u002Fmetastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.",[29,55,134,57,135],"Renal Cell Carcinoma","Cervix Cancer",[137,138,139],"CAR-T","CD70","CD70-positive advanced\u002Fmetastatic solid tumors","2025-05-26",{"date":142,"type":34},"2025-05-31",{"date":144,"type":34},"2022-05-30",{"date":146,"type":21},"2027-05-30",{"name":148,"class":41},"Weijia Fang, MD",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":42},"100528795","phase-2-definitive-radiation-for-high-risk-spine-metastases-100528795","NCT06165419","Definitive Radiation for High-Risk Spine Metastases","A Phase II Study Evaluating Definitive Radiosurgical Decompression in Patients With High-Risk Spinal Metastases","Eligible patients must have:\n\n* Any pathologically proven solid tumor diagnosis not of central nervous system origin with radiographic or pathologic evidence of metastatic disease\n* Metastatic spine involvement documented by imaging\n* Involvement of maximum 3 contiguous vertebral bodies at the index site\n* Intact neurologic function, or only minor neurologic deficits with muscle strength greater or equal to 4 out of 5 with or without steroids\n* An evaluation by an radiation oncology and orthopedic spine\u002Fneurosurgery attending\n* ECOG Performance Status of 0-3\n\nPatients are ineligible if they have:\n\n* An unstable spine defined as a Spinal Instability Neoplastic Score (SINS) greater than 12\n* Had previous surgery or radiation to address the target spinal metastases\n* Radiosensitive tumors (e.g. small cell lung cancer, lymphoma, multiple myeloma, and germ-cell tumors)",{"count":157,"type":21},26,[159],"PHASE2","This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery",[162,163,164,29,165,166,167,168],"Metastatic Cancer","Metastatic Lung Cancer","Metastatic Breast Cancer","Metastatic Tumor of Bone","Metastatic Tumor to the Spine","Spine Metastases","Metastasis","2025-05-09",{"date":171,"type":34},"2025-05-14",{"date":173,"type":34},"2023-12-14",{"date":175,"type":21},"2026-05-31",{"name":177,"class":41},"Stony Brook University",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":186,"minAge":4,"maxAge":4,"enrollmentInfo":187,"targetDuration":189,"studyType":190,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100552451","evaluation-of-clinical-outcomes-of-chemotherapy-or-androgen-receptor-targeting-agent-alone-or-combined-or-radiotherapy-on-primary-tumor-in-addition-to-androgen-deprivation-therapy-in-hormone-sensitive-metastatic-prostate-cancer-patients-100552451","NCT06473259","Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients","Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals","ECHOS","Inclusion Criteria:\n\n1. histologically confirmed diagnosis of adenocarcinoma of the prostate, metastatic, not undergoing previous treatment (except hormone therapy initiated no more than 4-6 months prior to docetaxel) for metastatic disease\n2. treatment with docetaxel, ARPI (alone or in combination) or with radiation therapy on the primary tumor in combination with ADT within normal clinical practice or expanded access programs initiated between January 2015 and December 2027.\n3. availability of inpatient and\u002For outpatient medical records for clinical data collection\n\nExclusion Criteria:\n\n1. histological diagnosis other than adenocarcinoma\n2. patients who have received multiple lines of ADT for mCSPC\n3. patients who have received docetaxel or ARTA for metastatic castration-resistant disease","MALE",{"count":188,"type":21},3000,"5 Years","OBSERVATIONAL","The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice",[193,194,29],"Prostate Cancer","Hormone Sensitive Prostate Cancer","2024-06-24",{"date":197,"type":34},"2024-06-25",{"date":199,"type":34},"2016-12-16",{"date":201,"type":21},"2028-12",{"name":203,"class":41},"Santa Chiara Hospital",3,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":220,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100545561","phase-1-a-clinical-study-of-anti-cd70-ucar-t-in-relapsed-or-refractory-solid-tumors-100545561","NCT06383507","A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors","A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Refractory or Relapsed Solid Tumors","Inclusion Criteria:\n\n1. Ability to understand and sign a written informed consent documen；\n2. Age ≥18 years old, male or female；\n3. Histopathological confirmed advanced or metastatic solid tumors failed to at least second-line treatment or initially diagnosed advanced\u002Fmetastatic solid tumors that have no NCCN guideline recommended standard first-line therapy；\n4. Histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) diagnosed as advanced\u002Fmetastatic solid tumor (positive tumor CD70 expression (tumor CD70 positive (IHC 2+) confirmed by histology or pathology));\n5. At least one measurable lesion at baseline per RECIST version 1.1；\n6. The expected survival time is more than 12 weeks;\n7. ECOG 0-1 points;\n8. The function of important organs is basically normal:Hematopoietic function:\n\n   * Hematopoietic function: neutrophils ≥ 1.5×109\u002FL, platelets ≥ 90×109\u002FL, hemoglobin ≥ 90g\u002FdL;\n   * Renal function: serum creatinine≤1.5×ULN;\n   * WBC≥3.0×109\u002FL,\n   * Liver function: Total bilirubin ≤ 1.5×ULN(Except Gilbert syndrome), extrahepatic metastasis：ALT and AST ≤ 3.0×ULN (Nonhepatic metastasis：it can be relaxed to ≤ 5.0×ULN);\n   * coagulation function：INR≤1.5×ULN，APTT≤1.5×ULN\n9. Subjects agree to use reliable and effective contraceptive methods for contraception within 6 months after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception);\n\nExclusion Criteria:\n\n1. Received anti-CD70 drug treatment before screening;\n2. Received anti-tumor therapy such as chemotherapy and targeted therapy within 2 weeks or at least 5 half-lives (whichever is longer) before Received;\n3. Received systemic corticosteroid therapy at doses greater than 10 mg\u002Fday prednisone (or equivalent doses of other corticosteroids) within 2 weeks prior to Received；\n4. Pregnant, lactating, or breastfeeding females;\n5. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA titer test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive; cytomegalovirus (CMV) DNA test positive;\n6. Have any of the following heart conditions:\n\n   New York Heart Association (NYHA) stage III or IV congestive heart failure; Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment; Clinically significant ventricular arrhythmia, echocardiography showed cardiac ejection fraction\\\u003C50%,\n7. Active\u002Fsymptomatic central nervous system metastases or meningeal metastases at the time of screening; subjects with brain metastases who have been treated must be confirmed to have no imaging evidence of progression ≥ 4 weeks after the end of treatment before they can be enrolled;\n8. Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation;\n9. Vaccination within 14 days of study enrollment;\n10. Received live attenuated vaccine within 4 weeks before screening;\n11. Malignant tumors other than the target tumor within 3 years prior to screening, except for the following: malignant tumors that have received radical treatment and no known active disease within ≥ 3 years prior to enrollment;\n12. Other investigators deem it inappropriate to participate in the study.\n13. Serious or uncontrollable systemic disease or any unstable systemic disease, including but not limited to uncontrolled hypertension, uncontrolled hyperglycemia, liver and kidney insufficiency or metabolic disease, central nervous system disease, etc","75 Years",{"count":214,"type":21},18,[24],"This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or relapsed solid tumors, and obtain recommended doses and infusion patterns.",[29,55,134,57,135,218,219],"Head and Neck Squamous Cell Carcinoma","Nasopharyngeal Carcinoma","NOT_YET_RECRUITING","2024-04-22",{"date":223,"type":34},"2024-04-25",{"date":221,"type":21},{"date":226,"type":21},"2029-04-21",{"name":228,"class":41},"Zhejiang University"]